FOLR1 and neoplasm: Especially, FOLR1 overexpression seems to be a tumor marker in a tissue-dependant manner and has gained interest for targeted therapies via antibodies (e.g. farletuzumab) or new folic acid-drug conjugates (e.g. vintafolide) for selective inhibition, which were tested in clinical trails [55].